ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 85 filers reported holding ACLARIS THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $201 | +737.5% | 29,424 | +1155.8% | 0.00% | – |
Q2 2023 | $24 | -97.6% | 2,343 | -98.1% | 0.00% | -100.0% |
Q1 2023 | $1,016 | +101500.0% | 125,627 | +134982.8% | 0.00% | – |
Q4 2022 | $1 | -100.0% | 93 | -90.4% | 0.00% | – |
Q3 2022 | $15,000 | -93.0% | 972 | -92.2% | 0.00% | – |
Q1 2022 | $215,000 | -38.7% | 12,482 | -48.4% | 0.00% | – |
Q4 2021 | $351,000 | +380.8% | 24,199 | +470.3% | 0.00% | – |
Q3 2021 | $73,000 | -7.6% | 4,243 | -6.5% | 0.00% | – |
Q2 2021 | $79,000 | -77.6% | 4,539 | -67.5% | 0.00% | -100.0% |
Q1 2021 | $352,000 | +1308.0% | 13,973 | +258.6% | 0.00% | – |
Q4 2020 | $25,000 | +212.5% | 3,897 | +21.9% | 0.00% | – |
Q3 2020 | $8,000 | – | 3,196 | +520.6% | 0.00% | – |
Q2 2020 | $0 | – | 515 | +104.4% | 0.00% | – |
Q4 2019 | $0 | -100.0% | 252 | -86.8% | 0.00% | – |
Q3 2019 | $2,000 | -80.0% | 1,914 | -58.8% | 0.00% | – |
Q2 2019 | $10,000 | -16.7% | 4,648 | +131.2% | 0.00% | – |
Q1 2019 | $12,000 | +500.0% | 2,010 | +443.2% | 0.00% | – |
Q4 2018 | $2,000 | – | 370 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management III, LLC | 1,954,904 | $49,264,000 | 43.26% |
COMMODORE CAPITAL LP | 1,028,084 | $25,908,000 | 10.32% |
Foresite Capital Management IV, LLC | 3,399,034 | $85,656,000 | 10.26% |
VR Adviser, LLC | 3,720,582 | $93,759,000 | 10.17% |
Parkman Healthcare Partners LLC | 1,709,136 | $43,070,000 | 10.00% |
Foresite Capital Management V, LLC | 1,258,243 | $31,708,000 | 9.32% |
Stenahm Asset Managment Ltd | 283,500 | $7,144,000 | 5.04% |
Samsara BioCapital, LLC | 1,022,612 | $25,770,000 | 4.75% |
SILVERARC CAPITAL MANAGEMENT, LLC | 336,737 | $8,486,000 | 4.63% |
Ghost Tree Capital, LLC | 600,000 | $15,120,000 | 3.55% |